Business
Director Appointment
Director Appointment.
About this update from Genincode Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3857H\n GENinCode PLC\n 06 April 2022\n \n \n \n \n \n \n \n GENinCode Plc\n \n \n (\"GENinCode\" or the \"Company\")\n \n \n \n \n \n Director appointment\n \n \n \n \n \n Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces the appointment to the Board of Felix Frueh, PhD (\"Felix\") as a Non-Executive Director.\n \n \n \n \n \n Felix is \n a senior life sciences executive with in-depth expertise in corporate, regulatory, and commercialisation strategies, with a particular focus on precision medicine. He has over \n 25 years of experience setting scientific and corporate strategy in precision medicine, and has founded several start-ups in the diagnostics and pharmaceutical sectors. He has worked in the regulatory space for 18 years, including five years working with the FDA. \n \n \n \n \n \n In addition to his FDA career, Felix oversaw the creation and operations of the world's largest next-generation, Clinical Laboratory Improvement Amendments (CLIA)-certified, whole human genome sequencing laboratory, as the Chief Scientific Officer of Human Longevity (HLI). Prior to this, he served as President of Medco Research Institute, Research Director for Pharmacogenetics of Transgenomic, and Assistant Director of Protogene Laboratories. He is Founder and Executive Partner of Opus Three, Co-Founder and Partner of Profound Ventures, and Co-Founder and Chief Scientific Officer of Selva Therapeutics. He also co-founded and formerly served as the Chief Executive Officer of Intellos Health.\n \n \n \n \n \n Felix received his PhD in biochemistry from the University of Basel in Switzerland and completed postdoctoral fellowships at the University of Basel and Stanford University. He has served as a consultant, strategic advisor, and Board member to numerous diagnostic, pharmaceutical, and other healthcare companies. He is the author of more than 100 peer-reviewed articles, book chapters, white papers, market analyses, strategies, and business plans.\n \n \n \n \n \n \n Matthew Walls, CEO of GENinCode Plc commented\n \n \n : \n \n \n \"\n \n \n We are delighted that Felix is joining as a Non-Executive Director. Felix can offer us invaluable insights into t...